70266-87-4

Upstream product

• 608-46-8 α-D-lyxopyranose 
• 116-11-0 2-Methoxypropene 
• 87-72-9 D-lyxose 
• 67-64-1 acetone 
• 7306-64-1 2,3,5,6-di-O-isopropylidene-D-mannono-1,4-lactone 
• 1114-34-7 D-lyxose 
• 532-20-7 D-lyxose 
• 77-76-9 2,2-dimethoxy-propane 
• 58-86-6 D-xylose 
• 50-69-1 D-ribose 
• 10257-32-6 D-ribose 
• 36468-53-8 β-D-ribofuranose 
• 131877-94-6 ((3aR,4S,6R,6aR)-6-Benzyloxy-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-methanol 
• 532-20-7 L-lyxofuranose 

Downstream Products

• 123564-95-4 1,5-di-O-(3,5-dinitrophenyl)carbamoyl-2,3-O-isopropylidene-α-D-lyxofuranose 
• 123564-94-3 5-O-(3,5-dinitrophenyl)carbamoyl-2,3-O-isopropylidene-α-D-lyxofuranose 
• 316364-82-6 Toluene-4-sulfonic acid (3aS,4R,6S,6aS)-6-hydroxy-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl ester 
• 1356163-83-1 (2R,3S,4R,Z)-3,4-O-isopropylidene-1-O-trityl-5-heptadecene-1,2,3,4-tetrol 
• 1356163-80-8 2,3-O-isopropylidene-5-O-trityl-α-D-lyxofuranose 
• 63029-07-2 methyl 2,3-O-isopropylidene-α-D-lyxofuranoside 
• 115509-13-2 (3aR,6aR)-2,2-Dimethyl-3a,6a-dihydro-cyclopenta[1,3]dioxol-4-one 
• 732308-58-6 (1S,2S,3S,4S,5R)-4-benzylamino-5-(hydroxymethyl)-1,2-isopropylidenecyclopentane-1,2,3-triol 
• 732308-54-2 (1R,2R,3S,4S)-1-bromo-2-O-(N-benzylcarbamoyl)-3,4-O-isopropylidene-5-methylenecyclopentane-2,3,4-triol 
• 732308-55-3 (1R,2R,3S,4S,5R)-1-bromo-2-O-(N-benzylcarbamoyl)-5-(hydroxymethyl)-3,4-O-isopropylidenecyclopentane-2,3,4-triol 
• 732308-51-9 (1R,2S,3R,4S)-1-(N-benzyl)-(N-tert-butoxycarbonyl)amino-3,4-O-isopropylidene-5-methylenecyclopentane-2,3,4-triol 
• 732308-52-0 (1S,2R,3S,4R,5R)-1,2-O-isopropylidene-4-(N-benzyl)-(N-tert-butoxycarbonyl)amino-5-(hydroxymethyl)cyclopentane-1,2,3-triol 
• 732308-57-5 (1S,2S,3S,4S,5R)-4-benzylamino-3-O-4-N-(oxomethylidene)-1,2-O-isopropylidene-5-((tert-butyl-dimethylsilyloxy)methyl)cyclopentane-1,2,3-triol 
• 732308-56-4 (1R,2R,3S,4S,5R)-2-O-(N-benzylcarbamoyl)-1-bromo-5-(O-tert-butyldimethylsilyloxymethyl)-3,4-O-isopropylidenecyclopentane-1,2,3-triol 

Relevant academic research and scientific papers

Chemoselective and Diastereoselective Synthesis of C-Aryl Nucleoside Analogues by Nickel-Catalyzed Cross-Coupling of Furanosyl Acetates with Aryl Iodides

Canonical nucleosides are vulnerable to enzymatic and chemical degradation, yet their stable mimics—C-aryl nucleosides—have demonstrated potential utility in medicinal chemistry, chemical biology, and synthetic biology, although current synthetic methods remain limited in terms of scope and selectivity. Herein, we report a cross-electrophile coupling to prepare C-aryl nucleoside analogues from readily available furanosyl acetates and aryl iodides. This nickel-catalyzed modular approach is characterized by mild reaction conditions, broad substrate scope, excellent β-selectivity, and high functional-group compatibility. The exclusive chemoselectivity with respect to the aryl iodide enables efficient preparation of a variety of C-aryl halide furanosides suitable for various downstream transformations. The practicality of this transformation is demonstrated through the synthesis of a potent analogue of a naturally occurring NF-κB activator.

Synthesis, biological evaluation, and molecular docking studies of deoxygenated C-glycosides as LpxC inhibitors

The bacterial deacetylase LpxC is a promising target for the development of novel antibiotics being selectively active against Gram-negative bacteria. In chiral pool syntheses starting from D- and L-ribose, a series regio- and stereoisomeric monohydroxyte

Synthesis of hydroxymethyl analogues of mannostatin A and their evaluation as inhibitors of GH38 α-mannosidases

A synthetic approach to hydroxymethyl analogues of mannostatin A starting froml-ribose is described. The key step employed in the synthesis of homomannostatin A was ring-opening of aziridine intermediates with sodium methanethiolate in DMF. Regioselectivity of these openings was investigated by quantum mechanics calculations. The synthesised hydroxymethyl analogues of mannostatin A were evaluated as inhibitors of three different GH38 α-mannosidases: the Golgi (GMIIb) and lysosomal (LManII) α-mannosidases fromDrosophila melanogaster, and commercial Jack bean α-mannosidase (JBMan) fromCanavalia ensiformis. The tested compounds exhibited inhibitory activity against GMIIb with IC50values in the range of 3-43 μM resulting in selectivity [IC50(LManII)/IC50(GMIIb)] similar to mannostatin A.

HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

Synthetic Study Aiming at the Tricyclic Core of 12- epi-JBIR-23/24

The synthetic study toward highly enantio- and diastereoselective synthesis of the tricyclic framework of 12-epi-JBIR-23/24, a natural product analogue showing inhibitory activity against four malignant pleural mesothelioma cell lines, is presented herein

NOVEL COMPOUND BASED ON VALEROLACTONE AND MEDICINE

This novel valerolactone-based compound is represented by formula (I). [In the formula, X represents an allyl group, an aryl group, an ethynyl group, or a butenyl group. Y represents a single bond or a hydroxymethylene group, and Z represents oxygen, a methylene group, or an imide group. In the formula, Y represents a single bond or a hydroxymethylene group, m is 0 or 1, and n is 1 or 2.]

Nucleoside analogs useful as PRMT5 inhibitors

The invention relates to the technical field of biological medicines, and particularly discloses a nucleoside analogue used as a PRMT5 inhibitor. According to the nucleoside analogue as shown in the formula (I) or the pharmaceutically acceptable salt of the nucleoside analogue, the nucleoside analogue or the pharmaceutically acceptable salt of the nucleoside analogue shows relatively high inhibition on the activity of PRMT5 and can be used for preventing and/or treating PRMT5-mediated diseases, and the PRMT5-mediated diseases comprise cell abnormal proliferative diseases.

COMPOUNDS TARGETING PRMT5

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS

Various embodiments provide STOPS? polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS? modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS? modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.

POLYMORPHIC COMPOUNDS AND USES THEREOF

The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.